Agenus Inc. (AGEN) 10-Year Financial Performance & Capital Metrics

AGEN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAgenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Show more

Revenue $103M -33.8%
EBITDA -$107M +26.6%
Net Income -$227M +7.5%
EPS (Diluted) -10.59 +23.0%
Gross Margin -50.79% +2.4%
EBITDA Margin -103.55% -10.9%
Operating Margin -116.44% -14.1%
Net Margin -219.61% -39.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -1.02 +37.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 7.2% over 5 years
✗Shares diluted 20.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.95%

5Y-7.17%

3Y-29.53%

TTM-33.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM84.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM80.97%

ROCE

10Y Avg-128.03%

5Y Avg-149.87%

3Y Avg-187.77%

Latest-383.15%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.82M	22.57M	42.88M	36.78M	150.05M	88.17M	295.67M	98.02M	156.31M	103.46M
Revenue Growth %	2.56%	-0.09%	0.9%	-0.14%	3.08%	-0.41%	2.35%	-0.67%	0.59%	-0.34%
Cost of Goods Sold+	70.44M	94.97M	116.13M	124.6M	168.34M	144.97M	182.08M	197.26M	237.68M	156.01M
COGS % of Revenue	2.84%	4.21%	2.71%	3.39%	1.12%	1.64%	0.62%	2.01%	1.52%	1.51%
Gross Profit+	-45.63M	-72.4M	-73.25M	-87.82M	-18.29M	-56.8M	113.59M	-99.23M	-81.37M	-52.55M
Gross Margin %	-1.84%	-3.21%	-1.71%	-2.39%	-0.12%	-0.64%	0.38%	-1.01%	-0.52%	-0.51%
Gross Profit Growth %	-1.97%	-0.59%	-0.01%	-0.2%	0.79%	-2.11%	3%	-1.87%	0.18%	0.35%
Operating Expenses+	28.37M	33.13M	33.74M	37.34M	51.85M	60.44M	87.84M	80.19M	78.18M	67.92M
OpEx % of Revenue	1.14%	1.47%	0.79%	1.02%	0.35%	0.69%	0.3%	0.82%	0.5%	0.66%
Selling, General & Admin	28.37M	33.13M	33.74M	37.34M	46.04M	59.22M	76.36M	81.01M	78.74M	71.88M
SG&A % of Revenue	1.14%	1.47%	0.79%	1.02%	0.31%	0.67%	0.26%	0.83%	0.5%	0.69%
Research & Development	70.44M	94.97M	116.13M	124.6M	168.34M	142.62M	178.61M	0	234.57M	155.53M
R&D % of Revenue	2.84%	4.21%	2.71%	3.39%	1.12%	1.62%	0.6%	-	1.5%	1.5%
Other Operating Expenses	-7.18M	-19.52M	-16.89M	-2.18M	-162.53M	-141.4M	-167.13M	-815K	-235.13M	-159.48M
Operating Income+	-80.7M	-107.48M	-103.8M	-123.82M	-70.14M	-117.23M	25.75M	-179.43M	-159.55M	-120.47M
Operating Margin %	-3.25%	-4.76%	-2.42%	-3.37%	-0.47%	-1.33%	0.09%	-1.83%	-1.02%	-1.16%
Operating Income Growth %	-0.86%	-0.33%	0.03%	-0.19%	0.43%	-0.67%	1.22%	-7.97%	0.11%	0.24%
EBITDA+	-66.5M	-102.53M	-97.79M	-117.53M	-63.48M	-110.06M	32.53M	-172.48M	-145.96M	-107.13M
EBITDA Margin %	-2.68%	-4.54%	-2.28%	-3.2%	-0.42%	-1.25%	0.11%	-1.76%	-0.93%	-1.04%
EBITDA Growth %	-0.59%	-0.54%	0.05%	-0.2%	0.46%	-0.73%	1.3%	-6.3%	0.15%	0.27%
D&A (Non-Cash Add-back)	14.2M	4.95M	6.01M	6.29M	6.66M	7.18M	6.79M	6.95M	13.59M	13.34M
EBIT	-86.67M	-109.68M	-101.82M	-136.77M	-70.11M	-121.81M	36.99M	-168.79M	-159.51M	-114.64M
Net Interest Income+	-6.6M	-17.32M	-18.87M	-25.27M	-41.45M	-61.08M	-65.72M	-61.86M	-97.92M	-117.63M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	6.6M	17.32M	18.87M	25.27M	41.45M	61.08M	65.72M	61.86M	97.92M	117.63M
Other Income/Expense	-12.57M	-19.52M	-16.89M	-38.22M	-41.42M	-65.66M	-54.47M	-51.23M	-97.89M	-111.8M
Pretax Income+	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Pretax Margin %	-3.54%	-5.63%	-2.81%	-4.41%	-0.74%	-2.07%	-0.1%	-2.35%	-1.65%	-2.24%
Income Tax+	-5.39M	-2.99M	0	-12.95M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.99%	0.97%	0.99%	0.83%	0.95%	0.95%	0.98%
Net Income+	-87.88M	-127M	-120.69M	-159.69M	-107.66M	-180.91M	-23.93M	-220.07M	-245.76M	-227.21M
Net Margin %	-3.54%	-5.63%	-2.81%	-4.34%	-0.72%	-2.05%	-0.08%	-2.25%	-1.57%	-2.2%
Net Income Growth %	-1.07%	-0.45%	0.05%	-0.32%	0.33%	-0.68%	0.87%	-8.2%	-0.12%	0.08%
Net Income (Continuing)	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	-2.08M	-5.98M	-7.83M	13.47M	6.38M	11.95M	19.96M
EPS (Diluted)+	-22.47	-29.17	-24.53	-28.83	-22.10	-21.00	-2.11	-15.64	-13.75	-10.59
EPS Growth %	-0.58%	-0.3%	0.16%	-0.18%	0.23%	0.05%	0.9%	-6.41%	0.12%	0.23%
EPS (Basic)	-22.47	-29.17	-24.53	-28.83	-22.10	-21.00	-2.11	-15.64	-13.75	-10.59
Diluted Shares Outstanding	3.91M	4.35M	4.92M	5.54M	6.75M	8.63M	11.45M	14.09M	17.89M	21.47M
Basic Shares Outstanding	3.91M	4.35M	4.92M	5.54M	6.75M	8.63M	11.45M	14.09M	17.89M	21.47M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	184.1M	91.31M	73.55M	74.81M	86.54M	113.78M	331.97M	213.12M	112.42M	45.57M
Cash & Short-Term Investments	171.67M	76.44M	60.19M	53.05M	61.81M	99.87M	306.92M	193.36M	76.11M	40.44M
Cash Only	171.67M	76.44M	60.19M	53.05M	61.81M	99.87M	291.93M	178.67M	76.11M	40.44M
Short-Term Investments	0	0	0	0	0	0	14.99M	14.68M	0	0
Accounts Receivable	9.8M	11.35M	1.13M	938.14K	16.29M	1.16M	1.52M	2.74M	25.84M	407K
Days Sales Outstanding	144.14	183.56	9.66	9.31	39.63	4.79	1.87	10.21	60.33	1.44
Inventory	88.2K	88.2K	79.49K	55.49K	7.42M	0	20.36M	13.83M	0	0
Days Inventory Outstanding	0.46	0.34	0.25	0.16	16.09	-	40.82	25.59	-	-
Other Current Assets	582.28K	838.54K	1.08M	1.5M	-6.41M	2.01M	-17.19M	-10.63M	2.37M	2.42M
Total Non-Current Assets+	58.13M	65.67M	82.2M	61.59M	68.8M	100.73M	133.98M	200.43M	201.5M	180.7M
Property, Plant & Equipment	15.31M	25.63M	26.18M	25.12M	33.69M	60.27M	91.08M	164.29M	163.03M	147.4M
Fixed Asset Turnover	1.62x	0.88x	1.64x	1.46x	4.45x	1.46x	3.25x	0.60x	0.96x	0.70x
Goodwill	22.79M	22.39M	23.05M	22.92M	23.19M	25.45M	24.88M	25.47M	24.72M	24.09M
Intangible Assets	18.76M	16.36M	31.76M	12.34M	10.5M	10.89M	8.49M	6.23M	4.41M	3.38M
Long-Term Investments	0	0	0	0	0	0	0	0	3.22M	0
Other Non-Current Assets	1.27M	1.28M	1.21M	1.21M	1.42M	4.12M	12.21M	7.12M	6.11M	5.83M
Total Assets+	242.23M	156.99M	138.4M	136.4M	155.34M	214.51M	465.96M	413.56M	313.91M	226.27M
Asset Turnover	0.10x	0.14x	0.31x	0.27x	0.97x	0.41x	0.63x	0.24x	0.50x	0.46x
Asset Growth %	2.25%	-0.35%	-0.12%	-0.01%	0.14%	0.38%	1.17%	-0.11%	-0.24%	-0.28%
Total Current Liabilities+	28.93M	40.85M	56.44M	68.06M	122.21M	129.88M	156.94M	188.95M	255.9M	221.4M
Accounts Payable	4.49M	5.43M	8.09M	13.62M	13.56M	17.02M	30.49M	40.94M	61.45M	61.47M
Days Payables Outstanding	23.26	20.86	25.42	39.91	29.41	42.84	61.11	75.75	94.36	143.81
Short-Term Debt	146.06K	146.06K	20.64M	146K	646K	833K	728K	575K	146K	2.7M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	18K	31K
Other Current Liabilities	15.87M	6.38M	3.22M	43.71M	48.15M	69.88M	75.66M	101.49M	141.21M	121.85M
Current Ratio	6.36x	2.24x	1.30x	1.10x	0.71x	0.88x	2.12x	1.13x	0.44x	0.21x
Quick Ratio	6.36x	2.23x	1.30x	1.10x	0.65x	0.88x	1.99x	1.05x	0.44x	0.21x
Cash Conversion Cycle	121.34	163.04	-15.51	-30.44	26.31	-	-18.42	-39.96	-	-
Total Non-Current Liabilities+	142.57M	155.26M	157.78M	242.88M	264.46M	296.13M	261.11M	279.51M	206.4M	311.29M
Long-Term Debt	114.33M	130.54M	142.39M	13.21B	13.38M	18.88M	12.82M	12.58M	12.77M	30.47M
Capital Lease Obligations	0	0	0	-13.2B	8.02M	34.06M	42.11M	63.33M	67.23M	54.55M
Deferred Tax Liabilities	0	0	0	182.82M	26.92M	0	0	0	0	0
Other Non-Current Liabilities	13.17M	12.37M	7.65M	-13.15B	188.44M	214.9M	194.97M	202.45M	125.26M	225.13M
Total Liabilities	171.5M	196.11M	214.22M	310.95M	386.67M	426.01M	418.05M	468.46M	462.3M	532.7M
Total Debt+	114.47M	130.69M	163.02M	13.36M	23.39M	55.73M	58.29M	78.43M	93.19M	94.87M
Net Debt	-57.2M	54.25M	102.84M	-39.7M	-38.41M	-44.14M	-233.64M	-100.25M	17.08M	54.43M
Debt / Equity	1.62x	-	-	-	-	-	1.22x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	1.79x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-7.18x	-	-	-
Interest Coverage	-12.23x	-6.21x	-5.50x	-4.90x	-1.69x	-1.92x	0.39x	-2.90x	-1.63x	-1.02x
Total Equity+	70.73M	-39.13M	-75.82M	-174.55M	-231.34M	-211.5M	47.91M	-54.9M	-148.38M	-306.42M
Equity Growth %	2.07%	-1.55%	-0.94%	-1.3%	-0.33%	0.09%	1.23%	-2.15%	-1.7%	-1.07%
Book Value per Share	18.09	-8.99	-15.41	-31.51	-34.28	-24.52	4.19	-3.90	-8.29	-14.27
Total Shareholders' Equity	70.73M	-39.13M	-75.82M	-172.47M	-225.36M	-203.67M	34.44M	-61.28M	-160.33M	-326.38M
Common Stock	863.91K	877.95K	1.02M	1.2M	1.38M	1.96M	2.57M	3.06M	3.94M	236K
Retained Earnings	-779.19M	-905.33M	-1.03B	-1.18B	-1.28B	-1.47B	-1.49B	-1.71B	-1.96B	-2.18B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.05M	-1.53M	-2.17M	-1.54M	-1.32M	2.77M	1.49M	915K	-955K	-1.4M
Minority Interest	0	0	0	-2.08M	-5.98M	-7.83M	13.47M	6.38M	11.95M	19.96M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-47.18M	-79.96M	-94.23M	-131.09M	-18.68M	-139.1M	10.14M	-175.37M	-224.2M	-158.31M
Operating CF Margin %	-1.9%	-3.54%	-2.2%	-3.56%	-0.12%	-1.58%	0.03%	-1.79%	-1.43%	-1.53%
Operating CF Growth %	-0.23%	-0.69%	-0.18%	-0.39%	0.86%	-6.45%	1.07%	-18.29%	-0.28%	0.29%
Net Income	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Depreciation & Amortization	14.2M	4.95M	6.01M	6.29M	6.66M	7.18M	6.79M	6.95M	13.59M	13.34M
Stock-Based Compensation	7.44M	13.19M	12.43M	7.63M	9.89M	10.42M	19.58M	18.34M	22.87M	17.39M
Deferred Taxes	-5.39M	14.73K	23.56K	10.91M	58K	0	0	0	0	0
Other Non-Cash Items	17.83M	18.48M	14.49M	5.95M	17.58M	17.25M	22.25M	5.92M	-13.98M	10.62M
Working Capital Changes	6.63M	10.4M	-6.48M	170.05K	58.68M	8.95M	-9.74M	24.08M	10.76M	32.6M
Change in Receivables	-9.33M	-1.55M	10.22M	196.35K	-15.36M	16.19M	-394K	122K	-23.46M	25.34M
Change in Inventory	7.5K	17.63M	8.71K	24K	55K	0	0	0	0	0
Change in Payables	2.67M	419.71K	1.65M	5.37M	-234K	2.77M	10.82M	6.49M	21.37M	2.01M
Cash from Investing+	-31.23M	17.6M	2.06M	-3.59M	-4.66M	-4.44M	-43.15M	-33.61M	3.4M	27K
Capital Expenditures	-3.59M	-12.52M	-3.12M	-3.6M	-4.66M	-3.47M	-33.81M	-53.06M	-9.95M	-576K
CapEx % of Revenue	0.14%	0.55%	0.07%	0.1%	0.03%	0.04%	0.11%	0.54%	0.06%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-20.46M	30.12M	120K	6.19K	0	0	5.66M	22M	3.36M	24K
Cash from Financing+	189.58M	-2.46M	80.54M	128.28M	31.32M	183.85M	225.26M	95.83M	119.87M	122.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-27.98M	-3.82M	775	204.39M	1.64M	4.47M	7.59M	898K	807K	74.5M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-50.77M	-92.48M	-97.35M	-134.69M	-23.34M	-142.56M	-23.67M	-228.44M	-234.16M	-158.89M
FCF Margin %	-2.05%	-4.1%	-2.27%	-3.66%	-0.16%	-1.62%	-0.08%	-2.33%	-1.5%	-1.54%
FCF Growth %	-0.24%	-0.82%	-0.05%	-0.38%	0.83%	-5.11%	0.83%	-8.65%	-0.03%	0.32%
FCF per Share	-12.98	-21.24	-19.78	-24.32	-3.46	-16.53	-2.07	-16.22	-13.09	-7.40
FCF Conversion (FCF/Net Income)	0.54x	0.63x	0.78x	0.82x	0.17x	0.77x	-0.42x	0.80x	0.91x	0.70x
Interest Paid	0	0	0	0	0	1.18M	1.15M	1.14M	3.17M	2.28M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-187.49%	-803.72%	-	-	-	-	-49.94%	-	-	-
Return on Invested Capital (ROIC)	-5144.37%	-562.55%	-369.42%	-	-	-	-	-	-	-
Gross Margin	-183.85%	-320.73%	-170.83%	-238.74%	-12.19%	-64.42%	38.42%	-101.24%	-52.05%	-50.79%
Net Margin	-354.12%	-562.6%	-281.48%	-434.14%	-71.75%	-205.19%	-8.09%	-224.51%	-157.22%	-219.61%
Debt / Equity	1.62x	-	-	-	-	-	1.22x	-	-	-
Interest Coverage	-12.23x	-6.21x	-5.50x	-4.90x	-1.69x	-1.92x	0.39x	-2.90x	-1.63x	-1.02x
FCF Conversion	0.54x	0.63x	0.78x	0.82x	0.17x	0.77x	-0.42x	0.80x	0.91x	0.70x
Revenue Growth	255.7%	-9.04%	89.95%	-14.21%	307.92%	-41.24%	235.34%	-66.85%	59.47%	-33.81%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Non Cash Royalty Revenue	-	-	-	-	-	-	-	-	114.57M	100.98M
Non Cash Royalty Revenue Growth	-	-	-	-	-	-	-	-	-	-11.87%
Other	-	-	-	-	-	-	-	-	-	2M
Other Growth	-	-	-	-	-	-	-	-	-	-
License Fee Revenue	-	-	-	-	-	-	-	-	25M	-
License Fee Revenue Growth	-	-	-	-	-	-	-	-	-	-
Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone	-	-	-	-	30.42M	47.55M	-	45.28M	-	-
Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone Growth	-	-	-	-	-	56.27%	-	-	-	-
Research And Development Revenue	-	-	-	900K	99.84M	700K	1.2M	1.6M	-	-
Research And Development Revenue Growth	-	-	-	-	10993.89%	-99.30%	71.43%	33.33%	-	-
Revenue	-	-	-	-	-	4.62M	6.7M	-	-	-
Revenue Growth	-	-	-	-	-	-	45.14%	-	-	-
Product And Service Other	-	-	-	-	4.68M	91K	184K	-	-	-
Product And Service Other Growth	-	-	-	-	-	-98.06%	102.20%	-	-	-
License And Service	-	-	-	15.5M	3.7M	-	-	-	-	-
License And Service Growth	-	-	-	-	-76.13%	-	-	-	-	-
Research And Development Services	-	-	-	4.2M	1.7M	-	-	-	-	-
Research And Development Services Growth	-	-	-	-	-59.52%	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	20.33M	38.88M	32.78M	149.36M	83.55M	288.96M	9.54M	114.57M	101.46M
UNITED STATES Growth	-	-	91.24%	-15.69%	355.58%	-44.06%	245.85%	-96.70%	1101.34%	-11.44%
Non-US	-	-	-	-	-	-	-	-	-	2M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
Non Us	-	-	-	-	-	4.62M	6.7M	-	-	-
Non Us Growth	-	-	-	-	-	-	45.14%	-	-	-
Europe	1.15M	2.24M	3.99M	4M	690K	-	-	-	-	-
Europe Growth	-	95.13%	78.14%	0.15%	-82.75%	-	-	-	-	-
U S	23.67M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Agenus Inc. (AGEN) reported $106.8M in revenue for fiscal year 2024. This represents a 3777% increase from $2.8M in 2011.

Agenus Inc. (AGEN) saw revenue decline by 33.8% over the past year.

Agenus Inc. (AGEN) reported a net loss of $35.2M for fiscal year 2024.

Dividend & Returns

Agenus Inc. (AGEN) had negative free cash flow of $89.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Agenus Inc. (AGEN) 10-Year Financial Performance & Capital Metrics

AGEN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $103M -33.8%
EBITDA -$107M +26.6%
Net Income -$227M +7.5%
EPS (Diluted) -10.59 +23.0%
Gross Margin -50.79% +2.4%
EBITDA Margin -103.55% -10.9%
Operating Margin -116.44% -14.1%
Net Margin -219.61% -39.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -1.02 +37.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 7.2% over 5 years
✗Shares diluted 20.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.95%

5Y-7.17%

3Y-29.53%

TTM-33.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM84.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM80.97%

ROCE

10Y Avg-128.03%

5Y Avg-149.87%

3Y Avg-187.77%

Latest-383.15%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.82M	22.57M	42.88M	36.78M	150.05M	88.17M	295.67M	98.02M	156.31M	103.46M
Revenue Growth %	2.56%	-0.09%	0.9%	-0.14%	3.08%	-0.41%	2.35%	-0.67%	0.59%	-0.34%
Cost of Goods Sold+	70.44M	94.97M	116.13M	124.6M	168.34M	144.97M	182.08M	197.26M	237.68M	156.01M
COGS % of Revenue	2.84%	4.21%	2.71%	3.39%	1.12%	1.64%	0.62%	2.01%	1.52%	1.51%
Gross Profit+	-45.63M	-72.4M	-73.25M	-87.82M	-18.29M	-56.8M	113.59M	-99.23M	-81.37M	-52.55M
Gross Margin %	-1.84%	-3.21%	-1.71%	-2.39%	-0.12%	-0.64%	0.38%	-1.01%	-0.52%	-0.51%
Gross Profit Growth %	-1.97%	-0.59%	-0.01%	-0.2%	0.79%	-2.11%	3%	-1.87%	0.18%	0.35%
Operating Expenses+	28.37M	33.13M	33.74M	37.34M	51.85M	60.44M	87.84M	80.19M	78.18M	67.92M
OpEx % of Revenue	1.14%	1.47%	0.79%	1.02%	0.35%	0.69%	0.3%	0.82%	0.5%	0.66%
Selling, General & Admin	28.37M	33.13M	33.74M	37.34M	46.04M	59.22M	76.36M	81.01M	78.74M	71.88M
SG&A % of Revenue	1.14%	1.47%	0.79%	1.02%	0.31%	0.67%	0.26%	0.83%	0.5%	0.69%
Research & Development	70.44M	94.97M	116.13M	124.6M	168.34M	142.62M	178.61M	0	234.57M	155.53M
R&D % of Revenue	2.84%	4.21%	2.71%	3.39%	1.12%	1.62%	0.6%	-	1.5%	1.5%
Other Operating Expenses	-7.18M	-19.52M	-16.89M	-2.18M	-162.53M	-141.4M	-167.13M	-815K	-235.13M	-159.48M
Operating Income+	-80.7M	-107.48M	-103.8M	-123.82M	-70.14M	-117.23M	25.75M	-179.43M	-159.55M	-120.47M
Operating Margin %	-3.25%	-4.76%	-2.42%	-3.37%	-0.47%	-1.33%	0.09%	-1.83%	-1.02%	-1.16%
Operating Income Growth %	-0.86%	-0.33%	0.03%	-0.19%	0.43%	-0.67%	1.22%	-7.97%	0.11%	0.24%
EBITDA+	-66.5M	-102.53M	-97.79M	-117.53M	-63.48M	-110.06M	32.53M	-172.48M	-145.96M	-107.13M
EBITDA Margin %	-2.68%	-4.54%	-2.28%	-3.2%	-0.42%	-1.25%	0.11%	-1.76%	-0.93%	-1.04%
EBITDA Growth %	-0.59%	-0.54%	0.05%	-0.2%	0.46%	-0.73%	1.3%	-6.3%	0.15%	0.27%
D&A (Non-Cash Add-back)	14.2M	4.95M	6.01M	6.29M	6.66M	7.18M	6.79M	6.95M	13.59M	13.34M
EBIT	-86.67M	-109.68M	-101.82M	-136.77M	-70.11M	-121.81M	36.99M	-168.79M	-159.51M	-114.64M
Net Interest Income+	-6.6M	-17.32M	-18.87M	-25.27M	-41.45M	-61.08M	-65.72M	-61.86M	-97.92M	-117.63M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	6.6M	17.32M	18.87M	25.27M	41.45M	61.08M	65.72M	61.86M	97.92M	117.63M
Other Income/Expense	-12.57M	-19.52M	-16.89M	-38.22M	-41.42M	-65.66M	-54.47M	-51.23M	-97.89M	-111.8M
Pretax Income+	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Pretax Margin %	-3.54%	-5.63%	-2.81%	-4.41%	-0.74%	-2.07%	-0.1%	-2.35%	-1.65%	-2.24%
Income Tax+	-5.39M	-2.99M	0	-12.95M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.99%	0.97%	0.99%	0.83%	0.95%	0.95%	0.98%
Net Income+	-87.88M	-127M	-120.69M	-159.69M	-107.66M	-180.91M	-23.93M	-220.07M	-245.76M	-227.21M
Net Margin %	-3.54%	-5.63%	-2.81%	-4.34%	-0.72%	-2.05%	-0.08%	-2.25%	-1.57%	-2.2%
Net Income Growth %	-1.07%	-0.45%	0.05%	-0.32%	0.33%	-0.68%	0.87%	-8.2%	-0.12%	0.08%
Net Income (Continuing)	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	-2.08M	-5.98M	-7.83M	13.47M	6.38M	11.95M	19.96M
EPS (Diluted)+	-22.47	-29.17	-24.53	-28.83	-22.10	-21.00	-2.11	-15.64	-13.75	-10.59
EPS Growth %	-0.58%	-0.3%	0.16%	-0.18%	0.23%	0.05%	0.9%	-6.41%	0.12%	0.23%
EPS (Basic)	-22.47	-29.17	-24.53	-28.83	-22.10	-21.00	-2.11	-15.64	-13.75	-10.59
Diluted Shares Outstanding	3.91M	4.35M	4.92M	5.54M	6.75M	8.63M	11.45M	14.09M	17.89M	21.47M
Basic Shares Outstanding	3.91M	4.35M	4.92M	5.54M	6.75M	8.63M	11.45M	14.09M	17.89M	21.47M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	184.1M	91.31M	73.55M	74.81M	86.54M	113.78M	331.97M	213.12M	112.42M	45.57M
Cash & Short-Term Investments	171.67M	76.44M	60.19M	53.05M	61.81M	99.87M	306.92M	193.36M	76.11M	40.44M
Cash Only	171.67M	76.44M	60.19M	53.05M	61.81M	99.87M	291.93M	178.67M	76.11M	40.44M
Short-Term Investments	0	0	0	0	0	0	14.99M	14.68M	0	0
Accounts Receivable	9.8M	11.35M	1.13M	938.14K	16.29M	1.16M	1.52M	2.74M	25.84M	407K
Days Sales Outstanding	144.14	183.56	9.66	9.31	39.63	4.79	1.87	10.21	60.33	1.44
Inventory	88.2K	88.2K	79.49K	55.49K	7.42M	0	20.36M	13.83M	0	0
Days Inventory Outstanding	0.46	0.34	0.25	0.16	16.09	-	40.82	25.59	-	-
Other Current Assets	582.28K	838.54K	1.08M	1.5M	-6.41M	2.01M	-17.19M	-10.63M	2.37M	2.42M
Total Non-Current Assets+	58.13M	65.67M	82.2M	61.59M	68.8M	100.73M	133.98M	200.43M	201.5M	180.7M
Property, Plant & Equipment	15.31M	25.63M	26.18M	25.12M	33.69M	60.27M	91.08M	164.29M	163.03M	147.4M
Fixed Asset Turnover	1.62x	0.88x	1.64x	1.46x	4.45x	1.46x	3.25x	0.60x	0.96x	0.70x
Goodwill	22.79M	22.39M	23.05M	22.92M	23.19M	25.45M	24.88M	25.47M	24.72M	24.09M
Intangible Assets	18.76M	16.36M	31.76M	12.34M	10.5M	10.89M	8.49M	6.23M	4.41M	3.38M
Long-Term Investments	0	0	0	0	0	0	0	0	3.22M	0
Other Non-Current Assets	1.27M	1.28M	1.21M	1.21M	1.42M	4.12M	12.21M	7.12M	6.11M	5.83M
Total Assets+	242.23M	156.99M	138.4M	136.4M	155.34M	214.51M	465.96M	413.56M	313.91M	226.27M
Asset Turnover	0.10x	0.14x	0.31x	0.27x	0.97x	0.41x	0.63x	0.24x	0.50x	0.46x
Asset Growth %	2.25%	-0.35%	-0.12%	-0.01%	0.14%	0.38%	1.17%	-0.11%	-0.24%	-0.28%
Total Current Liabilities+	28.93M	40.85M	56.44M	68.06M	122.21M	129.88M	156.94M	188.95M	255.9M	221.4M
Accounts Payable	4.49M	5.43M	8.09M	13.62M	13.56M	17.02M	30.49M	40.94M	61.45M	61.47M
Days Payables Outstanding	23.26	20.86	25.42	39.91	29.41	42.84	61.11	75.75	94.36	143.81
Short-Term Debt	146.06K	146.06K	20.64M	146K	646K	833K	728K	575K	146K	2.7M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	18K	31K
Other Current Liabilities	15.87M	6.38M	3.22M	43.71M	48.15M	69.88M	75.66M	101.49M	141.21M	121.85M
Current Ratio	6.36x	2.24x	1.30x	1.10x	0.71x	0.88x	2.12x	1.13x	0.44x	0.21x
Quick Ratio	6.36x	2.23x	1.30x	1.10x	0.65x	0.88x	1.99x	1.05x	0.44x	0.21x
Cash Conversion Cycle	121.34	163.04	-15.51	-30.44	26.31	-	-18.42	-39.96	-	-
Total Non-Current Liabilities+	142.57M	155.26M	157.78M	242.88M	264.46M	296.13M	261.11M	279.51M	206.4M	311.29M
Long-Term Debt	114.33M	130.54M	142.39M	13.21B	13.38M	18.88M	12.82M	12.58M	12.77M	30.47M
Capital Lease Obligations	0	0	0	-13.2B	8.02M	34.06M	42.11M	63.33M	67.23M	54.55M
Deferred Tax Liabilities	0	0	0	182.82M	26.92M	0	0	0	0	0
Other Non-Current Liabilities	13.17M	12.37M	7.65M	-13.15B	188.44M	214.9M	194.97M	202.45M	125.26M	225.13M
Total Liabilities	171.5M	196.11M	214.22M	310.95M	386.67M	426.01M	418.05M	468.46M	462.3M	532.7M
Total Debt+	114.47M	130.69M	163.02M	13.36M	23.39M	55.73M	58.29M	78.43M	93.19M	94.87M
Net Debt	-57.2M	54.25M	102.84M	-39.7M	-38.41M	-44.14M	-233.64M	-100.25M	17.08M	54.43M
Debt / Equity	1.62x	-	-	-	-	-	1.22x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	1.79x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-7.18x	-	-	-
Interest Coverage	-12.23x	-6.21x	-5.50x	-4.90x	-1.69x	-1.92x	0.39x	-2.90x	-1.63x	-1.02x
Total Equity+	70.73M	-39.13M	-75.82M	-174.55M	-231.34M	-211.5M	47.91M	-54.9M	-148.38M	-306.42M
Equity Growth %	2.07%	-1.55%	-0.94%	-1.3%	-0.33%	0.09%	1.23%	-2.15%	-1.7%	-1.07%
Book Value per Share	18.09	-8.99	-15.41	-31.51	-34.28	-24.52	4.19	-3.90	-8.29	-14.27
Total Shareholders' Equity	70.73M	-39.13M	-75.82M	-172.47M	-225.36M	-203.67M	34.44M	-61.28M	-160.33M	-326.38M
Common Stock	863.91K	877.95K	1.02M	1.2M	1.38M	1.96M	2.57M	3.06M	3.94M	236K
Retained Earnings	-779.19M	-905.33M	-1.03B	-1.18B	-1.28B	-1.47B	-1.49B	-1.71B	-1.96B	-2.18B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.05M	-1.53M	-2.17M	-1.54M	-1.32M	2.77M	1.49M	915K	-955K	-1.4M
Minority Interest	0	0	0	-2.08M	-5.98M	-7.83M	13.47M	6.38M	11.95M	19.96M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-47.18M	-79.96M	-94.23M	-131.09M	-18.68M	-139.1M	10.14M	-175.37M	-224.2M	-158.31M
Operating CF Margin %	-1.9%	-3.54%	-2.2%	-3.56%	-0.12%	-1.58%	0.03%	-1.79%	-1.43%	-1.53%
Operating CF Growth %	-0.23%	-0.69%	-0.18%	-0.39%	0.86%	-6.45%	1.07%	-18.29%	-0.28%	0.29%
Net Income	-87.88M	-127M	-120.69M	-162.04M	-111.56M	-182.89M	-28.72M	-230.66M	-257.44M	-232.27M
Depreciation & Amortization	14.2M	4.95M	6.01M	6.29M	6.66M	7.18M	6.79M	6.95M	13.59M	13.34M
Stock-Based Compensation	7.44M	13.19M	12.43M	7.63M	9.89M	10.42M	19.58M	18.34M	22.87M	17.39M
Deferred Taxes	-5.39M	14.73K	23.56K	10.91M	58K	0	0	0	0	0
Other Non-Cash Items	17.83M	18.48M	14.49M	5.95M	17.58M	17.25M	22.25M	5.92M	-13.98M	10.62M
Working Capital Changes	6.63M	10.4M	-6.48M	170.05K	58.68M	8.95M	-9.74M	24.08M	10.76M	32.6M
Change in Receivables	-9.33M	-1.55M	10.22M	196.35K	-15.36M	16.19M	-394K	122K	-23.46M	25.34M
Change in Inventory	7.5K	17.63M	8.71K	24K	55K	0	0	0	0	0
Change in Payables	2.67M	419.71K	1.65M	5.37M	-234K	2.77M	10.82M	6.49M	21.37M	2.01M
Cash from Investing+	-31.23M	17.6M	2.06M	-3.59M	-4.66M	-4.44M	-43.15M	-33.61M	3.4M	27K
Capital Expenditures	-3.59M	-12.52M	-3.12M	-3.6M	-4.66M	-3.47M	-33.81M	-53.06M	-9.95M	-576K
CapEx % of Revenue	0.14%	0.55%	0.07%	0.1%	0.03%	0.04%	0.11%	0.54%	0.06%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-20.46M	30.12M	120K	6.19K	0	0	5.66M	22M	3.36M	24K
Cash from Financing+	189.58M	-2.46M	80.54M	128.28M	31.32M	183.85M	225.26M	95.83M	119.87M	122.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-27.98M	-3.82M	775	204.39M	1.64M	4.47M	7.59M	898K	807K	74.5M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-50.77M	-92.48M	-97.35M	-134.69M	-23.34M	-142.56M	-23.67M	-228.44M	-234.16M	-158.89M
FCF Margin %	-2.05%	-4.1%	-2.27%	-3.66%	-0.16%	-1.62%	-0.08%	-2.33%	-1.5%	-1.54%
FCF Growth %	-0.24%	-0.82%	-0.05%	-0.38%	0.83%	-5.11%	0.83%	-8.65%	-0.03%	0.32%
FCF per Share	-12.98	-21.24	-19.78	-24.32	-3.46	-16.53	-2.07	-16.22	-13.09	-7.40
FCF Conversion (FCF/Net Income)	0.54x	0.63x	0.78x	0.82x	0.17x	0.77x	-0.42x	0.80x	0.91x	0.70x
Interest Paid	0	0	0	0	0	1.18M	1.15M	1.14M	3.17M	2.28M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-187.49%	-803.72%	-	-	-	-	-49.94%	-	-	-
Return on Invested Capital (ROIC)	-5144.37%	-562.55%	-369.42%	-	-	-	-	-	-	-
Gross Margin	-183.85%	-320.73%	-170.83%	-238.74%	-12.19%	-64.42%	38.42%	-101.24%	-52.05%	-50.79%
Net Margin	-354.12%	-562.6%	-281.48%	-434.14%	-71.75%	-205.19%	-8.09%	-224.51%	-157.22%	-219.61%
Debt / Equity	1.62x	-	-	-	-	-	1.22x	-	-	-
Interest Coverage	-12.23x	-6.21x	-5.50x	-4.90x	-1.69x	-1.92x	0.39x	-2.90x	-1.63x	-1.02x
FCF Conversion	0.54x	0.63x	0.78x	0.82x	0.17x	0.77x	-0.42x	0.80x	0.91x	0.70x
Revenue Growth	255.7%	-9.04%	89.95%	-14.21%	307.92%	-41.24%	235.34%	-66.85%	59.47%	-33.81%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Non Cash Royalty Revenue	-	-	-	-	-	-	-	-	114.57M	100.98M
Non Cash Royalty Revenue Growth	-	-	-	-	-	-	-	-	-	-11.87%
Other	-	-	-	-	-	-	-	-	-	2M
Other Growth	-	-	-	-	-	-	-	-	-	-
License Fee Revenue	-	-	-	-	-	-	-	-	25M	-
License Fee Revenue Growth	-	-	-	-	-	-	-	-	-	-
Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone	-	-	-	-	30.42M	47.55M	-	45.28M	-	-
Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone Growth	-	-	-	-	-	56.27%	-	-	-	-
Research And Development Revenue	-	-	-	900K	99.84M	700K	1.2M	1.6M	-	-
Research And Development Revenue Growth	-	-	-	-	10993.89%	-99.30%	71.43%	33.33%	-	-
Revenue	-	-	-	-	-	4.62M	6.7M	-	-	-
Revenue Growth	-	-	-	-	-	-	45.14%	-	-	-
Product And Service Other	-	-	-	-	4.68M	91K	184K	-	-	-
Product And Service Other Growth	-	-	-	-	-	-98.06%	102.20%	-	-	-
License And Service	-	-	-	15.5M	3.7M	-	-	-	-	-
License And Service Growth	-	-	-	-	-76.13%	-	-	-	-	-
Research And Development Services	-	-	-	4.2M	1.7M	-	-	-	-	-
Research And Development Services Growth	-	-	-	-	-59.52%	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	20.33M	38.88M	32.78M	149.36M	83.55M	288.96M	9.54M	114.57M	101.46M
UNITED STATES Growth	-	-	91.24%	-15.69%	355.58%	-44.06%	245.85%	-96.70%	1101.34%	-11.44%
Non-US	-	-	-	-	-	-	-	-	-	2M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
Non Us	-	-	-	-	-	4.62M	6.7M	-	-	-
Non Us Growth	-	-	-	-	-	-	45.14%	-	-	-
Europe	1.15M	2.24M	3.99M	4M	690K	-	-	-	-	-
Europe Growth	-	95.13%	78.14%	0.15%	-82.75%	-	-	-	-	-
U S	23.67M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Agenus Inc. (AGEN) reported $106.8M in revenue for fiscal year 2024. This represents a 3777% increase from $2.8M in 2011.

Agenus Inc. (AGEN) saw revenue decline by 33.8% over the past year.

Agenus Inc. (AGEN) reported a net loss of $35.2M for fiscal year 2024.

Dividend & Returns

Agenus Inc. (AGEN) had negative free cash flow of $89.3M in fiscal year 2024, likely due to heavy capital investments.